ISCT 2023: Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy
Share This
Latest Posts
Categories
- Chief Marketing Officer (111)
- Public Relations (68)
- Marketing (328)
- Advertising (186)
- Videos (20)